The use of DPP-4 inhibitors in DM patients with HFpEF, but not HFmrEF or HFrEF, was associated with a lower incidence of composite of cardiovascular death or HF hospitalization in these patients but not in HFmrEF or HFrEF [61]. This evidence concerns the gene DPP4 and hydrops fetalis.